Peter Blattmann

Fit-for-purpose application of LC–MS in protein bioanalysis, case studies shared within the European Bioanalysis Forum Hybrid MS team

Amanda Wilson, R J Lucey, Emmanuel Njumbe Ediage, Katrin Schroeter et autres

ch, es, us, de (code pays fourni par la source)

Lucerastat effect on kidney function in patients with Fabry disease: Results from the ongoing open label-extension (OLE) of the phase 3 clinical program

Eric Wallace, Dominique P. Germain, Peter Blattmann, Aline Frey et autres

Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study

Dominique P. Germain, Peter Blattmann, Markus Cybulla, Aline Frey et autres

Navigating IVDR challenges for pharmacokinetic, anti-drug antibodies, and biomarker assays in early clinical research: a recommendation from the European Bioanalysis Forum

Philip Timmerman, Matthew Barfield, Jon G. Bartlet, Peter Blattmann et autres

be, ch, gb, us, de, it (code pays fourni par la source)

Sinbaglustat ameliorates disease pathology in a murine model of GM1 gangliosidosis without affecting CNS ganglioside levels

Rouven Wannemacher, Lorna Jubran-Rudolf, Isabel Zdora, Eva Leitzen et autres

de, ch (code pays fourni par la source)

Efficacy of IDOR‐1117‐2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis

Paulina Kulig, Pijus Brazauskas, Madeleine Suffiotti, Emilie Raoult et autres

ch (code pays fourni par la source)

Perspective on LC-MS(/MS) for biotherapeutic and biomarker proteins in research and regulated Bioanalysis: a consolidation of more than a decade of experience across the European Bioanalysis Forum community (Part 2: “The How”)

Nico van de Merbel, Mark Jean Gnoth, Amanda Wilson, Peter Blattmann et autres

ch, gb, fr, de, us, sg, ru, nl, dk, it (code pays fourni par la source)

Perspective on LC-MS(/MS) for biotherapeutic and biomarker proteins in research and regulated Bioanalysis: a consolidation of more than a decade of experience across the European Bioanalysis Forum community (Part 1: “The What”)

Amanda Wilson, Mark Jean Gnoth, Nico van de Merbel, Peter Blattmann et autres

gb, us, sg, ch, fr, de, ru, nl, dk, it (code pays fourni par la source)

Abstract P437: Correlation between plasma CT-proET-1 and renal dysfunction in patients with resistant hypertension. A biomarker analysis of the PRECISION study.

Peter Blattmann, Marc Iglarz, Roland F. Dreier, Parisa Danaietash et autres

ch (code pays fourni par la source)

Abstract 19: Effect of the endothelin receptor antagonist aprocitentan on plasma endothelin, renin and aldosterone concentrations in patients with resistant hypertension. A biomarker analysis of the PRECISION study.

Marc Iglarz, Peter Blattmann, Roland F. Dreier, Parisa Danaietash et autres

ch (code pays fourni par la source)

A European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assays

Kyra J. Cowan, Ulrich Kunz, Peter Blattmann, Pratiksha Gulati et autres

de, cn, au, ch, us, dk, gb, it, hr (code pays fourni par la source)

WS05.02 A novel uniquely efficacious type of CFTR corrector with complementary mode of action

Valentina Marchesin, Lucile Monnier, Peter Blattmann, Florent Chevillard et autres

ch (code pays fourni par la source)